229 related articles for article (PubMed ID: 30540177)
41. BACE inhibitors as potential therapeutics for Alzheimer's disease.
Evin G; Kenche VB
Recent Pat CNS Drug Discov; 2007 Nov; 2(3):188-99. PubMed ID: 18221231
[TBL] [Abstract][Full Text] [Related]
42. pH-Dependent Population Shift Regulates BACE1 Activity and Inhibition.
Ellis CR; Shen J
J Am Chem Soc; 2015 Aug; 137(30):9543-6. PubMed ID: 26186663
[TBL] [Abstract][Full Text] [Related]
43. Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production.
Shimizu H; Tosaki A; Kaneko K; Hisano T; Sakurai T; Nukina N
Mol Cell Biol; 2008 Jun; 28(11):3663-71. PubMed ID: 18378702
[TBL] [Abstract][Full Text] [Related]
44. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease.
Yuan J; Venkatraman S; Zheng Y; McKeever BM; Dillard LW; Singh SB
J Med Chem; 2013 Jun; 56(11):4156-80. PubMed ID: 23509904
[TBL] [Abstract][Full Text] [Related]
45. Development and Structural Modification of BACE1 Inhibitors.
Gu T; Wu WY; Dong ZX; Yu SP; Sun Y; Zhong Y; Lu YT; Li NG
Molecules; 2016 Dec; 22(1):. PubMed ID: 28025519
[TBL] [Abstract][Full Text] [Related]
46. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
47. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and evaluation of arylquinones as BACE1 inhibitors, β-amyloid peptide aggregation inhibitors, and destabilizers of preformed β-amyloid fibrils.
Ortega A; Rincón Á; Jiménez-Aliaga KL; Bermejo-Bescós P; Martín-Aragón S; Molina MT; Csákÿ AG
Bioorg Med Chem Lett; 2011 Apr; 21(8):2183-7. PubMed ID: 21441028
[TBL] [Abstract][Full Text] [Related]
49. Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease.
Linning P; Haussmann U; Beyer I; Weidlich S; Schieb H; Wiltfang J; Klafki HW; Knölker HJ
Org Biomol Chem; 2012 Oct; 10(41):8216-35. PubMed ID: 22930158
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
[TBL] [Abstract][Full Text] [Related]
51. Synthesis, in vitro biological evaluation and molecular docking studies of benzimidamides as potential BACE1 inhibitors.
Niu Y; Gao H; Xu F; Wang C; Liu P; Yang G; Sun Q; Xu P
Chem Biol Drug Des; 2012 Nov; 80(5):775-80. PubMed ID: 22882897
[TBL] [Abstract][Full Text] [Related]
52. A comparative molecular dynamics study on BACE1 and BACE2 flap flexibility.
Kumalo HM; Soliman ME
J Recept Signal Transduct Res; 2016 Oct; 36(5):505-14. PubMed ID: 26804314
[TBL] [Abstract][Full Text] [Related]
53. Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands.
Iraji A; Khoshneviszadeh M; Firuzi O; Khoshneviszadeh M; Edraki N
Bioorg Chem; 2020 Apr; 97():103649. PubMed ID: 32101780
[TBL] [Abstract][Full Text] [Related]
54. New evolutions in the BACE1 inhibitor field from 2014 to 2018.
Hsiao CC; Rombouts F; Gijsen HJM
Bioorg Med Chem Lett; 2019 Mar; 29(6):761-777. PubMed ID: 30709653
[TBL] [Abstract][Full Text] [Related]
55. Design and synthesis of bicyclic acetals as Beta Secretase (BACE1) inhibitors.
Innocenti R; Lenci E; Menchi G; Pupi A; Trabocchi A
Bioorg Med Chem; 2017 Oct; 25(19):5077-5083. PubMed ID: 28359674
[TBL] [Abstract][Full Text] [Related]
56. Computational methods in the discovery and design of BACE-1 inhibitors.
Kacker P; Bottegoni G; Cavalli A
Curr Med Chem; 2012; 19(36):6095-111. PubMed ID: 23072352
[TBL] [Abstract][Full Text] [Related]
57. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011).
Probst G; Xu YZ
Expert Opin Ther Pat; 2012 May; 22(5):511-40. PubMed ID: 22512789
[TBL] [Abstract][Full Text] [Related]
58. Oleic acid and linoleic acid from Tenebrio molitor larvae inhibit BACE1 activity in vitro: molecular docking studies.
Youn K; Yun EY; Lee J; Kim JY; Hwang JS; Jeong WS; Jun M
J Med Food; 2014 Feb; 17(2):284-9. PubMed ID: 24548007
[TBL] [Abstract][Full Text] [Related]
59. In silico screening of potential β-secretase (BACE1) inhibitors from VIETHERB database.
Nhung NT; Duong N; Phung HTT; Vo QV; Tam NM
J Mol Model; 2022 Feb; 28(3):60. PubMed ID: 35156141
[TBL] [Abstract][Full Text] [Related]
60. From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis.
Nozal V; García-Rubia A; Cuevas EP; Pérez C; Tosat-Bitrián C; Bartolomé F; Carro E; Ramírez D; Palomo V; Martínez A
Angew Chem Int Ed Engl; 2021 Aug; 60(35):19344-19354. PubMed ID: 34169618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
